Health CarePharmaceuticals & Biotechnology
  • Price (JPY)2,901.00
  • Today's Change13.00 / 0.45%
  • Shares traded625.20k
  • 1 Year change31.80%
  • Beta0.7114
Data delayed at least 20 minutes, as of Sep 25 2020 07:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

Kyowa Kirin Co., Ltd., formerly Kyowa Hakko Kirin Co., Ltd. is a Japan-based company principally engaged in the manufacture and sale of medical drugs. The Company operates through two business segments. Pharmaceuticals segment conducts research, development, manufacture and sale of pharmaceuticals and other products. Bio-chemicals segment is involved in the research, development, manufacture and sale of pharmaceuticals and industrial raw materials mainly for amino acid and nucleic acid related substances, as well as healthcare products.

  • Revenue in JPY (TTM)312.22bn
  • Net income in JPY46.82bn
  • Incorporated1949
  • Employees5.27k
  • Location
    Kyowa Kirin Co LtdOtemachi Financial City Grand Cube1-9-2, Ote-machiCHIYODA-KU 100-0004JapanJPN
  • Phone+81 352057200
  • Fax+81 352057182
  • Websitehttps://www.kyowakirin.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
TAKARA BIO INC.32.85bn2.63bn345.11bn1.49k131.125.2755.6710.5021.8621.86272.83543.820.45321.675.0222,123,230.003.653.643.963.9960.5557.928.057.755.02--0.0024.35-3.565.894.4331.72-3.6939.77
JCR Pharmaceuticals Co Ltd24.81bn3.08bn388.09bn667.00127.9511.3084.4015.6493.5693.56799.731,059.530.50600.81313.5937,191,900.006.286.778.768.2668.4567.1612.4212.601.30--0.346231.377.008.01-27.919.7429.2711.58
ROHTO PHARMACEUTICAL CO., LTD.185.06bn15.13bn419.22bn6.62k26.842.9219.152.27132.27132.271,617.741,215.110.92322.264.7827,958,600.007.495.6010.338.1360.5659.628.116.191.64--0.052324.232.584.4157.2612.299.186.47
Hisamitsu Pharmaceutical Co Inc136.64bn16.89bn458.19bn2.75k26.141.7721.573.35205.84205.841,666.303,040.540.46542.983.8449,778,140.005.806.606.527.5761.8362.8312.4612.975.72--0.006236.07-1.68-2.10-2.66-0.096-5.220.739
Medipal Holdings Corp3.24tn37.00bn525.24bn13.60k13.130.88038.070.1623163.54163.5414,325.732,440.171.9619.984.60237,981,800.003.052.738.457.937.227.231.551.361.06--0.061822.812.242.5210.509.9012.5211.30
Peptidream Inc4.15bn401.90m542.04bn107.001,679.4530.73572.86130.772.562.5632.52140.100.20834.471.8038,738,950.002.02--2.27--62.69--9.70--4.63--0.00--------------
Sumitomo Dainippon Pharma Co Ltd499.11bn52.31bn545.52bn6.46k10.411.018.761.09131.66131.661,256.261,361.800.48831.893.8777,296,740.004.384.727.016.6672.6175.058.978.740.5755--0.318224.385.115.39-16.1921.411.549.24
Alfresa Holdings Corporation2.67tn38.10bn555.58bn12.07k13.141.0411.140.208179.97179.9712,620.842,273.801.9616.534.32221,259,600.002.802.857.688.107.537.511.431.411.04--0.002324.092.202.19-3.4811.935.3110.94
Nippon Shinyaku Co., Ltd.117.16bn17.75bn597.84bn2.03k32.293.8328.105.10263.54263.541,739.482,219.450.67462.062.6757,827,740.0010.238.4211.969.9655.0453.4915.1712.463.73--0.0029.791.677.833.4623.457.5128.03
Santen Pharmaceutical Co Ltd239.98bn23.41bn838.72bn4.11k35.842.7422.063.4958.4858.48599.52766.360.6032.642.9258,418,210.005.398.866.3110.6960.2361.668.9414.982.7337.740.13331.843.228.34-26.09-0.3469-32.624.18
Kyowa Kirin Co Ltd312.22bn46.82bn1.56tn5.27k33.152.2624.054.9987.1287.12580.941,276.890.40631.813.4759,279,
ONO PHARMACEUTICAL CO., LTD.293.35bn64.87bn1.76tn3.56k25.702.8522.076.00129.57129.57585.911,168.730.44462.393.6882,401,970.009.868.0511.219.1973.1173.1322.1719.492.49--0.013244.991.3116.5815.8435.70-6.334.56
Eisai Co., Ltd707.20bn124.52bn2.80tn11.00k21.713.9817.563.95434.37434.372,467.022,367.370.68442.544.0164,302,870.0012.116.5716.358.6175.8168.8517.6911.261.86--0.113465.688.214.8792.1023.0022.211.30
Data as of Sep 25 2020. Currency figures normalised to Kyowa Kirin Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

14.61%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 31 Aug 202019.06m3.53%
Asset Management One Co., Ltd.as of 15 Apr 202014.77m2.74%
Nikko Asset Management Co., Ltd.as of 30 Jul 20208.19m1.52%
Daiwa Asset Management Co. Ltd.as of 31 Aug 20207.83m1.45%
The Vanguard Group, Inc.as of 31 Aug 20207.23m1.34%
Massachusetts Financial Services Co.as of 31 Jul 20206.09m1.13%
BlackRock Fund Advisorsas of 03 Sep 20204.40m0.82%
Norges Bank Investment Managementas of 31 Dec 20194.17m0.77%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 03 Sep 20203.85m0.71%
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 18 Sep 20203.33m0.62%
More ▼
Data from 31 Dec 2019 - 30 Jun 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.